INVA Q4 2025 Earnings — Innoviva, Inc. Revenue & Financial Results | Market Cap Arena

INVAInnoviva, Inc.

$1B

Q4 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$118M+28.6% YoY

Gross Profit

$76M64.1% margin

Operating Income

$39M33.0% margin

Net Income

$164M139.1% margin

EPS (Diluted)

$1.94

QoQ Revenue Growth

+9.5%

Cash Flow

Operating Cash Flow

$55M

Free Cash Flow

$53M

Stock-Based Comp.

$16M

Balance Sheet

Total Assets

$1.6B

Total Liabilities

$462M

Stockholders' Equity

$1.2B

Cash & Equivalents

$551M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$118M	$92M	+28.6%
Gross Profit	$76M	$85M	-10.7%
Operating Income	$39M	$43M	-9.6%
Net Income	$164M	$20M	+707.4%

Revenue Segments

Product

$59M52%

Royalty

$55M48%

License And Other Revenue

$653,0001%